Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARROWHEAD PHARMACEUTICALS, INC.

(ARWR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
57.81(c) 54.13(c) 53.79(c) 52.51(c) 50.84(c) Last
593 920 588 221 596 548 884 255 717 387 Volume
+0.40% -6.37% -0.63% -2.38% -3.18% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 293 M - -
Net income 2022 -75,1 M - -
Net cash position 2022 235 M - -
P/E ratio 2022 -56,6x
Yield 2022 -
Sales 2023 298 M - -
Net income 2023 -174 M - -
Net cash position 2023 176 M - -
P/E ratio 2023 -32,5x
Yield 2023 -
Capitalization 5 314 M 5 314 M -
EV / Sales 2022 17,3x
EV / Sales 2023 17,2x
Nbr of Employees 329
Free-Float -
More Financials
Company
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis,... 
More about the company
Ratings of Arrowhead Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about ARROWHEAD PHARMACEUTICALS, INC.
01/21Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
BU
01/19Goldman Sachs Assumes Arrowhead Pharmaceuticals at Buy with $85 Price Target
MT
01/12Arrowhead Pharmaceuticals Commences Dosing in Phase 3 Trial of Treatment for Familial C..
MT
01/12Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment o..
BU
01/12Arrowhead Pharmaceuticals Inc Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatme..
CI
01/10INSIDER SELL : Arrowhead Pharmaceuticals
MT
01/07INSIDER SELL : Arrowhead Pharmaceuticals
MT
2021Arrowhead Pharmaceuticals to Invest up to $250 Million in New Facilities in Verona, Wis..
MT
2021Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
AQ
2021ARROWHEAD PHARMACEUTICALS : Initiates Project to Build New Manufacturing and Lab Facilitie..
PU
2021ARROWHEAD PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
2021Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
BU
2021Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
CI
2021INSIDER SELL : Arrowhead Pharmaceuticals
MT
2021Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4..
BU
More news
News in other languages on ARROWHEAD PHARMACEUTICALS, INC.
01/12Arrowhead Pharmaceuticals commence le dosage du traitement du syndrome de la chylomicro..
01/12Arrowhead Pharmaceuticals Inc. lance l'étude de phase 3 PALISADE sur ARO-APOC3 pour le ..
2021Arrowhead Pharmaceuticals va investir jusqu'à 250 millions de dollars dans de nouvelles..
2021Les actions du secteur de la santé restent stables avant l'ouverture de la séance de ma..
2021VENTE D'INITIÉS : Arrowhead Pharmaceuticals
More news
Analyst Recommendations on ARROWHEAD PHARMACEUTICALS, INC.
More recommendations
Chart ARROWHEAD PHARMACEUTICALS, INC.
Duration : Period :
Arrowhead Pharmaceuticals, Inc. Technical Analysis Chart | ARWR | US04280A1007 | MarketScreener
Technical analysis trends ARROWHEAD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 50,84 $
Average target price 87,75 $
Spread / Average Target 72,6%
EPS Revisions
Managers and Directors
Christopher Richard Anzalone President, Chief Executive Officer & Director
Kenneth Allen Myszkowski Chief Financial Officer
Douglass B. Given Chairman
Javier San Martin Chief Medical Officer
Jeff Ketelhut Vice President-Information Technology & Systems
Sector and Competitors
1st jan.Capi. (M$)
ARROWHEAD PHARMACEUTICALS, INC.-23.32%5 314
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624